The Indian diagnostics industry is a crucial segment of the healthcare sector, playing a pivotal role in disease detection, prognosis, treatment planning, and post-treatment monitoring. According to market research, the Indian diagnostic services market was valued at USD 14.57 billion in 2022 and is projected to reach USD 44.9 billion by FY32, reflecting a significant growth trajectory. This expansion is driven by several factors, including rising healthcare spending by an ageing population, increasing disposable incomes, growing awareness for preventive healthcare, and the introduction of advanced diagnostic tests.
The Indian government is actively supporting the growth of the diagnostics sector. The Union Budget 2024 allocated Rs 90,658.63 crore to the Ministry of Health and Family Welfare, representing a 12.59% increase over the previous year. This increased allocation signifies the government’s commitment to improving healthcare infrastructure and accessibility, potentially benefiting diagnostic service providers. The industry itself is witnessing a trend towards consolidation, with larger players acquiring regional competitors to expand their market share. Additionally, companies are embracing digitalization and artificial intelligence to enhance customer experience by offering home-based diagnostic services.
An analysis of the capex figures for below companies reveals a dynamic picture. The table below summarizes the capex figures for these companies, along with their market capitalization and key growth metrics.
| S.No | Company Name | CMP (Rs) | PE | Market Cap (Rs crore) | Capex FY24 | Capex FY23 | Capex FY22 | Sales Var 3Yrs % | Profit Var 3Yrs % |
| 1 | Dr. Lal Pathlabs | 2,304.95 | 58.96 | 19,451 | 33.3 | 44 | 474.5 | 14.88 | 1.81 |
| 2 | Metropolis Health. | 1,767.75 | 72.42 | 9,036 | 46.46 | 52.48 | 30.662 | 10.27 | -0.23 |
| 3 | Vijaya Diagnostic | 708.05 | 61.67 | 6,961 | -3.331 | 124.58 | 120.92 | 13.29 | 12.62 |
| 4 | Thyrocare Tech. | 619.5 | 49.77 | 3,264 | 74.96 | 41.55 | 14.9 | 6.65 | -18.95 |
| 5 | Amrutanjan Healthcare | 766.4 | 50.72 | 2,232 | – | 8.88 | 23.46 | 13.23 | 16.65 |
| 6 | Krsnaa Diagnostics | 569.95 | 32.4 | 1,848 | 146.839 | 134.726 | 131.13 | 21.55 | 36.91 |
| 7 | Vimta Labs | 496.6 | 26.71 | 1,104 | 72.33 | 49.56 | 38.68 | 20.37 | 90.73 |
| 8 | Nidan Labs. & Health | 36.35 | 14.7 | 52 | – | – | 6.47 | 4.27 | 67.56 |
As observed, the total capex for FY24 (Rs 370.56 crore) is substantially lower compared to FY22 (Rs 840.72 crore). This decrease can be partially attributed to incomplete data, as some companies haven’t yet reported full-year figures for FY24. However, the data suggests a potential shift in capex strategies among diagnostic companies.
| S.No | Company Name | Market Cap (Rs crore) | Three Year Capex | Capex as % of Mcap | Sales Var 3Yrs % | Profit Var 3Yrs % |
| 1 | Dr. Lal Pathlabs | 19,451 | 551.8 | 2.84% | 14.88 | 1.81 |
| 2 | Metropolis Health. | 9,036 | 129.602 | 1.43% | 10.27 | -0.23 |
| 3 | Vijaya Diagnostic | 6,961 | 242.169 | 3.48% | 13.29 | 12.62 |
| 4 | Thyrocare Tech. | 3,264 | 131.41 | 4.03% | 6.65 | -18.95 |
| 5 | Amrutanjan Healthcare | 2,232 | 32.34 | 1.45% | 13.23 | 16.65 |
| 6 | Krsnaa Diagnostics | 1,848 | 412.694 | 22.33% | 21.55 | 36.91 |
| 7 | Vimta Labs | 1,104 | 160.57 | 14.54% | 20.37 | 90.73 |
| 8 | Nidan Labs. & Health | 52 | 6.47 | 12.44% | 4.27 | 67.56 |
An interesting finding is the correlation between capex intensity (capex as a percentage of market capitalization) and profit growth. Companies like Krsnaa Diagnostics, Vimta Labs and Nidan Labs which have shown high capex intensity, have also witnessed impressive profit growth. This suggests that these companies might be strategically investing in expansion and technological advancements, potentially leading to future revenue growth.
Recognizing the evolving customer preferences, major players in the diagnostic industry are actively integrating technology and digitalization into their operations. The increased demand for post-pandemic testing, coupled with the need for faster results and accurate diagnosis, has compelled companies to adopt a customer-centric approach.
A key strategy involves focusing on the home-visit segment. Diagnostic companies are striving to provide services at patients’ homes that are comparable to lab visits. This involves digitizing the entire home-visit process by employing artificial intelligence (AI) and machine learning (ML) techniques. These technologies cater to the growing customer preference for an omnichannel experience, offering seamless service options.
The Indian diagnostics industry presents a promising outlook, driven by a confluence of factors. Rising healthcare spending, increasing disposable incomes, and growing awareness for preventive healthcare are fueling market expansion. Additionally, government support through increased budgetary allocations towards healthcare infrastructure is fostering a positive environment. The analysis of capex trends reveals a dynamic picture among diagnostic companies. While some companies are aggressively investing in expansion and technological advancements, others are adopting a more cautious approach. The impact of these strategies on profitability demands further evaluation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. The information is based on various secondary sources on the internet and is subject to change. Please consult with a financial expert before making investment decisions.
Published on: May 9, 2024, 5:14 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
